Ionis Pharmaceuticals Inc (IONS)
38.76
+0.37
(+0.96%)
USD |
NASDAQ |
Nov 01, 16:00
38.76
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Revenue (Quarterly): 225.25M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 225.25M |
| March 31, 2024 | 119.50M |
| December 31, 2023 | 324.50M |
| September 30, 2023 | 144.21M |
| June 30, 2023 | 188.41M |
| March 31, 2023 | 130.52M |
| December 31, 2022 | 151.89M |
| September 30, 2022 | 159.77M |
| June 30, 2022 | 133.79M |
| March 31, 2022 | 141.92M |
| December 31, 2021 | 440.01M |
| September 30, 2021 | 133.09M |
| June 30, 2021 | 125.75M |
| March 31, 2021 | 111.61M |
| December 31, 2020 | 290.28M |
| September 30, 2020 | 160.08M |
| June 30, 2020 | 145.54M |
| March 31, 2020 | 133.37M |
| December 31, 2019 | 493.68M |
| September 30, 2019 | 167.89M |
| June 30, 2019 | 163.81M |
| March 31, 2019 | 297.21M |
| December 31, 2018 | 192.12M |
| September 30, 2018 | 145.40M |
| June 30, 2018 | 117.75M |
| Date | Value |
|---|---|
| March 31, 2018 | 144.42M |
| December 31, 2017 | 167.79M |
| September 30, 2017 | 118.31M |
| June 30, 2017 | 112.27M |
| March 31, 2017 | 115.80M |
| December 31, 2016 | 186.50M |
| September 30, 2016 | 110.93M |
| June 30, 2016 | 38.47M |
| March 31, 2016 | 36.87M |
| December 31, 2015 | 51.57M |
| September 30, 2015 | 49.12M |
| June 30, 2015 | 120.43M |
| March 31, 2015 | 62.58M |
| December 31, 2014 | 84.86M |
| September 30, 2014 | 44.06M |
| June 30, 2014 | 57.08M |
| March 31, 2014 | 28.16M |
| December 31, 2013 | 42.25M |
| September 30, 2013 | 23.58M |
| June 30, 2013 | 38.09M |
| March 31, 2013 | 43.36M |
| December 31, 2012 | 19.87M |
| September 30, 2012 | 11.60M |
| June 30, 2012 | 47.34M |
| March 31, 2012 | 23.24M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
111.61M
Minimum
Mar 2021
493.68M
Maximum
Dec 2019
197.53M
Average
145.54M
Median
Jun 2020
Revenue (Quarterly) Benchmarks
| Biogen Inc | 2.466B |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Biomarin Pharmaceutical Inc | 745.74M |
| Rigel Pharmaceuticals Inc | 36.84M |
| Apellis Pharmaceuticals Inc | 199.68M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -66.26M |
| Total Expenses (Quarterly) | 291.34M |
| EPS Diluted (Quarterly) | -0.45 |
| Enterprise Value | 5.311B |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -29.42% |
| Earnings Yield | -6.50% |
| Normalized Earnings Yield | -7.883 |